The purpose of this research is to determine how well brincidofovir works compared to cidofovir in treating adenovirus infection in both children and adults who have received a transplant. Both medications are designed to fight viral infections, but they work in slightly different ways. The study will evaluate which treatment is more effective at eliminating the virus from the blood.

During the study, participants will receive either brincidofovir or cidofovir through intravenous infusion. The treatment period may last up to 12 weeks, during which doctors will monitor how well the medications work and check for any side effects. The study team will track various aspects of the participants’ health, including how quickly the virus levels decrease and how long patients need to stay in the hospital.

The purpose of the study is to assess how well the T cell treatment works in clearing the viral infections in patients who have not responded to other treatments. Participants in the study will receive the T cell treatment through an infusion, which is a method of delivering the treatment directly into the bloodstream. The study will monitor the patients over a period of time to see if the viral infections are reduced or cleared and to observe any side effects or changes in health status.

Throughout the study, various health indicators will be checked, such as the presence of the virus in the blood and any symptoms related to the infections. The study will also look at the overall health and survival of the patients, as well as any potential side effects from the treatment. The goal is to determine if the T cell treatment can provide a new option for patients with these challenging viral infections after stem cell transplantation.

The purpose of the study is to determine if a single dose of betamethasone, in addition to standard fever-reducing treatments like paracetamol or ibuprofen, can help more children become fever-free within 24 hours. Children participating in the study will receive either betamethasone or a placebo, and their body temperature will be monitored to see how quickly their fever resolves. The study will also look at other factors, such as the level of throat pain and whether hospitalization is needed.

Participants in the study will be children between the ages of 6 months and 6 years who have a confirmed Adenovirus infection and a fever. The study aims to provide valuable information on whether betamethasone can be an effective treatment option for reducing fever in children with Adenovirus infections. The trial is expected to run until June 2025, with recruitment starting in March 2024.